Skip to main content
Download PDF

Energy intake and expenditure in patients with Alzheimer’s disease and mild cognitive impairment: the NUDAD project

Alzheimer's Research & Therapy volume 12, Article number: 116 (2020) Cite this article

Abstract

Background

Malnutrition is common in patients with Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) and is associated with institutionalization and increased mortality. Malnutrition is the result of a negative energy balance, which could be due to reduced dietary intake and/or higher energy expenditure. To study underlying mechanisms for malnutrition, we investigated dietary intake and resting energy expenditure (REE) of patients with AD dementia, MCI, and controls. In addition, we studied associations of global cognition (Mini-Mental State Examination (MMSE)) and AD biomarkers with dietary intake and REE.

Methods

We included 219 participants from the NUDAD project, 71 patients with AD dementia (age 68 ± 8 years, 58% female, MMSE 24 ± 3), 52 with MCI (67 ± 8 years, 42% female, MMSE 26 ± 2), and 96 controls (62 ± 7 years, 52% female, MMSE 28 ± 2). We used a 238-item food frequency questionnaire to assess dietary intake (energy, protein, carbohydrate, and fat). In a subgroup of 92 participants (30 patients with AD dementia, 22 with MCI, and 40 controls) we measured REE with indirect calorimetry. Between-group differences in dietary intake and REE were tested with ANOVAs. In the total sample, linear regression analyses were used to explore potential associations of MMSE score and AD biomarkers with dietary intake and REE. All analyses were adjusted for age, sex, education, and body mass index or fat-free mass.

Results

Patients with AD dementia and MCI did not differ from controls in total energy intake (1991 ± 71 and 2172 ± 80 vs 2022 ± 61 kcal/day, p > 0.05) nor in protein, carbohydrate, or fat intake. Patients with AD dementia and MCI had a higher REE than controls (1704 ± 41 and 1754 ± 47 vs 1569 ± 34 kcal/day, p < 0.05). We did not find any association of MMSE score or AD biomarkers with dietary intake or REE.

Conclusions

We found a higher REE, despite similar energy intake in patients with AD and MCI compared to controls. These findings suggest that elevated metabolism rather than reduced energy intake explains malnutrition in AD. These results could be useful to optimize dietary advice for patients with AD dementia and MCI.

Background

Malnutrition in patients with Alzheimer’s disease (AD) dementia is associated with a higher rate of institutionalization and increased mortality [1, 2]. We previously found that even patients with mild AD dementia and mild cognitive impairment (MCI) have a worse nutritional status, assessed with the Mini Nutritional Assessment (MNA) [3], than controls [4]. Malnutrition reflects a negative energy balance, which can arise from a reduced energy intake, a higher energy expenditure, or a combination of both. To date, it is unclear what causes the negative energy balance in patients with MCI or AD dementia. It is conceivable that impaired memory affects dietary intake [5], which would fit with the notion of a reduced dietary intake as a result of cognitive decline. Alternatively, one could hypothesize that dietary intake or energy expenditure change as an effect of Alzheimer-related brain changes, reflected by AD biomarkers in cerebrospinal fluid (CSF).

Forgetting to eat, no longer being able to use eating utensils, or lack of appetite are hypothesized to cause a reduced dietary intake in patients with AD dementia [5, 6]. However, only one study found that energy intake of patients with AD dementia was lower than that of controls [7], while other studies found no differences in energy intake between patients with AD dementia and controls [8,9,10]. This inconsistency might be caused by different dietary assessment methods and different inclusion criteria for patients with AD dementia and controls. Resting energy expenditure (REE) accounts for about 70% of daily expenditure and is hypothesized to be higher in patients with AD dementia than controls [6]. This is supported by one study [11]; however, two other studies found no differences in REE between patients with AD dementia and controls [8, 12]. Furthermore, in patients with AD dementia, total energy expenditure might also be elevated due to a higher physical activity level, possibly due to wandering [13]. Contrarily, studies that measured physical activity found that patients with AD dementia and MCI were actually less physically active and performed their activities at lower intensities than controls [14, 15].

Thus, the results of studies focusing on aspects of energy balance are conflicting, probably due to the broad range of AD severity within the studies. Moreover, patients with MCI were not included in studies that assessed dietary intake, and in only one study measuring physical activity, while changes in nutritional status already occur in pre-dementia stages [4]. Therefore, the aim of this paper is to compare dietary intake, REE, and physical activity of patients with AD dementia and MCI with cognitively normal controls. In addition, we assessed associations between global cognition and AD biomarkers with dietary intake and REE.

Methods

Participants

The NUDAD (Nutrition, the Unrecognized Determinant in Alzheimer’s Disease) study is a prospective cohort study, investigating nutritional determinants in AD dementia and pre-dementia stages, with a 3-year clinical follow-up [4]. The total NUDAD cohort includes 552 participants of the Amsterdam Dementia Cohort who visited the Alzheimer center between September 2015 and August 2017 and were diagnosed with AD dementia, MCI, or subjective cognitive decline (SCD) and had a Mini-Mental State Examination (MMSE) score > 16 [16]. All patients underwent a standardized dementia screening, including medical history and neurological examination, neuropsychological assessment, and laboratory tests [17]. Patients were diagnosed with MCI and probable AD dementia according to the corresponding National Institute on Aging-Alzheimer’s Association criteria [18, 19]. As controls, we used individuals with SCD, who presented with memory complaints but performed normal on all clinical examinations (i.e., criteria for MCI, dementia or any other neurological or psychiatric disorder that could explain their cognitive complaints not met) [17]. For the current study, data of 225 participants who filled in a food frequency questionnaire (FFQ) [20] were used. They were representative for the total NUDAD cohort (n = 552) regarding age, sex, MMSE score, and body mass index (BMI).

Of the 225 participants, a subgroup of 92 participated in additional measurements of REE, physical activity, and a 3-day food diary. For this subgroup, inclusion criteria were age ≥ 50 years, MMSE score ≥ 19, being medically stable (assessed by physician), and having sufficient knowledge of the Dutch language. Exclusion criteria were being a current smoker, having a major psychiatric disorder, having neurological disorders other than AD known to influence smell and taste, having a severe food allergy or severe disease of the digestive tract, or being recently diagnosed with cancer other than basal cell carcinoma of the skin.

Dietary intake

Two dietary assessment methods were used: the HELIUS FFQ (n = 225) and a 3-day food diary in the subgroup (n = 92). The FFQ provides general information about habitual intake, whereas the food diary provides detailed information about dietary intake on specific days. The methods therefore provide complementary information. The FFQ is a self-administrated questionnaire asking about the frequency, amount, and type of 238 items consumed in the past month [20]. On the 3-day food diary, participants report their dietary intake on three consecutive days including one weekend day and includes all meals, snacks, and beverages consumed. The diaries were cross-checked with the participant by a qualified nutritionist to ensure that they were complete and of sufficient detail. Dietary data were coded in the software programme Compl-eat (http://www.compleat.nl) [21]. For both the FFQ and the 3-day food diary, daily intakes of food items and their nutrients were calculated using the Dutch food composition table 2013 [22]. A dietician performed a data check: the highest and lowest percentiles for energy, protein, fruit, and vegetable intake were checked for errors in amount or coding. Participants were excluded if more than ten items were missing on the FFQ or if they reported an implausible energy intake of < 500 or > 3500 kcal for women and < 800 or > 4000 kcal for men on the FFQ or 3-day food diary [23]. On the FFQ, two participants had more than ten items missing and four reported an implausible energy intake, leaving 219 participants for data analysis. No participants reported an implausible energy intake on the 3-day food diary. For both the FFQ and food diary, daily energy intake in kcal as well as protein, carbohydrate, and fat intake in energy percentage (EN%) were derived.

Energy expenditure

Daily REE of participants in the subgroup was assessed in fasting state (> 4 h) using indirect calorimetry (Quark RMR, COSMED Benelux BV, the Netherlands) for a duration of 30 min. Data from the first 5 min were automatically removed. Participants were placed in supine position with the ventilated hood over their head. Oxygen consumption and carbon dioxide production were analyzed continuously and converted into energy expenditure with the Weir equation [24]. One participant suffered from hyperventilation during the measurement, and three participants were not in a fasted state, leaving data of 88 participants for analysis.

In a subgroup, time spent physically active was measured using ActiGraph accelerometers (model wGT3X-BT, ActiGraph Inc., Pensacola, USA). The accelerometer was attached to a tight elastic belt and worn around the waist on the right side for 1 week. Participants were instructed to wear the accelerometer during waking hours and during all activities that do not involve water (e.g., showering). Data available of at least four valid days (> 10 h wear time per day) was downloaded and processed using the manufacturer’s software (Actilife v6.13.4, ActiGraph Pensacola, USA) [25]. Forty-four participants returned the accelerometer, two of them did not wear it due to sickness, six had less than four valid days, and five had less than 10 h wear time per day, leaving data of 31 participants for analysis. Based on the number of counts per minute (c/m), physical activity was measured in separate intensity categories: light (100–2019 c/m), which was further subdivided into low-light (100–759 c/m, e.g., light household activities) and high-light (760–2019 c/m, e.g., walking), and moderate to vigorous (> 2020 c/m, e.g., cycling) [25]. Total physical activity was the sum of light and moderate to vigorous physical activity.

Determinants

Global cognition was measured with the MMSE, with a maximum score of 30 and a higher score indicating better global cognition [16]. AD biomarkers β-amyloid 42 (Aβ42), total tau (tau), and phosphorylated tau (p-tau) were measured in cerebrospinal fluid (CSF). CSF was obtained by lumbar puncture using a 25-gauge needle and collected in 10 ml polypropylene tubes (Sarstedt) following standardized protocols [26]. Aβ42, tau, and p-tau concentrations were determined with sandwich ELISAs (Fujirebio, Ghent, Belgium) [27]. Aβ42 concentrations were adjusted for the drift that occurred over the years [28], and data were available of 148 participants.

Other variables

Descriptive characteristics included the following: age, sex, BMI from measured weight and height (kg/m2), level of education, and living situation (with partner/children, alone). Level of education was assessed using the Verhage classification system [29] and categorized into low (scores 1–3), intermediate (scores 4 and 5), and high (scores 6 and 7). Fat-free mass (FFM, kg) was estimated using bio-electrical impedance analysis (Bodystat Quadscan 4000) and the formula of Kyle [30] and available of 195 participants. Furthermore, nutritional status was evaluated with the Mini Nutritional Assessment (MNA) [3]. To avoid that differences in MNA score were driven by differences in cognitive performance, we excluded the item on neuropsychological problems. MNA score range from 0 to 28 with a higher score indicating a better nutritional status and available of 163 participants.

Statistical analyses

We compared participant characteristics, dietary intake, and energy expenditure between diagnosis groups using ANOVA with post-hoc Bonferroni adjusted t tests and chi-square tests where appropriate. ANOVAs of dietary intake were adjusted for age, sex, education, and BMI; for REE, ANOVAs were adjusted for FFM instead of BMI, and ANOVAs of physical activity were adjusted for age, sex, and education. We performed sensitivity analyses restricted to participants with a confirmed CSF biomarker profile for the dietary intake and REE analyses. In the total sample, linear regression analyses were used to explore potential associations of MMSE score and each AD biomarker (independent variables) with dietary intake or REE (dependent variables in separate models). The associations of MMSE and AD biomarkers with dietary intake were adjusted for age, sex, education, and BMI, whereas the associations with REE were adjusted for age, sex, education, and FFM. Significance was set at p value < 0.05. All statistical analyses were performed with Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL) version 24.0 for Windows.

Results

Table 1 presents characteristics of the 219 participants with complete dietary intake data assessed by the FFQ (supplementary table A shows study sample characteristics for 3-day food diary, REE and physical activity). Patients with AD dementia and MCI were older and had a lower MMSE score compared to controls, and patients with AD dementia were lower educated than patients with MCI and controls. Patients with AD dementia had lower Aβ42 levels and higher tau and p-tau levels than controls. Twenty-one controls and five patients with AD dementia did not have a matching CSF biomarker profile. Groups did not differ in BMI or MNA score.

Table 1 Characteristics of total study sample with FFQ available (n = 219) according to diagnosis group
Full size table

Dietary intake

Energy intake assessed by FFQ was 1991 ± 71 kcal/day for patients with AD dementia, 2172 ± 82 kcal/day for patients with MCI, and 2022 ± 61 kcal/day for controls and did not differ across groups (Table 2). When we analyzed specific macronutrients, groups also did not differ in protein, carbohydrate, or fat intakes. Similarly, energy, protein, carbohydrate, and fat intake assessed with the 3 day-food diary did not differ across groups. Restricting the analysis to participants with a confirmed biomarker profile showed similar results (Supplementary table B). Adjusted linear regression analyses showed no associations of MMSE score or AD biomarkers with dietary intake by FFQ (Table 3).

Table 2 Dietary intake and energy expenditure according to diagnosis group
Full size table
Table 3 Associations of global cognition and AD biomarkers with dietary intake and REE
Full size table

Energy expenditure

REE was higher in patients with AD dementia and MCI (1704 ± 41 and 1754 ± 47 kcal/day) than in controls (1569 ± 34 kcal/day) (Table 2). There was no interaction with sex. REE per kg FFM was highest in patients with MCI and lowest in controls. Comparable results were found when restricting the analysis to participants with confirmed biomarker profile (Supplementary table B). Adjusted linear regression analyses showed no associations between MMSE score or AD biomarkers and REE (Table 3). Total time spent physically active did not differ across groups nor the time spent on physical activity at a certain intensity level (Table 2).

Discussion

The main finding of this cross-sectional study is that patients with AD dementia and MCI had a higher REE than controls, despite a similar energy intake and physical activity level. These results suggest that the negative energy balance causing malnutrition in patients with AD dementia and MCI is more likely a consequence of a higher energy expenditure than of a reduced energy intake.

The higher REE of patients with AD dementia compared to controls confirms the results of one previous study [11]. We extend on this former study, by showing a higher REE in patients with MCI as well. In contrast to these findings, two other studies found similar REE in patients with AD dementia and controls [8, 12]. These two studies included patients with moderate and severe dementia (MMSE range 0–26), while we included patients with mild to moderate AD dementia (MMSE range 19–29), which might explain the discrepancies. Our results fit with the notion that REE is elevated in the beginning phase of the disease, as patients with MCI had the highest REE. Subsequently, REE declines in the more severe stages of the disease when FFM declines as well. Possibly, in the very early disease stages including MCI, cortical hypermetabolism as a compensatory mechanism causes higher energy needs of the brain [31] and therefore a higher REE. Another hypothesis is that the increased energy expenditure is caused by hypothalamic dysfunction, which has been showed in mice [32]. However, other underlying mechanisms, like elevated cortisol levels or stress, could not be excluded and need to be studied as well.

In contrast with former literature, diagnosis groups did not differ in physical activity [14, 15]. This is likely due to the wear location of the accelerometer, as previous studies used devices on the wrist (measuring mainly arm activity), while our device were attached to the waist and measured total body activity. Accelerometers worn at the hip or waist are generally more accurate than those worn on the wrist [33]. The average time the three groups spent physically active is comparable to Dutch older adults of the Longitudinal Aging Study Amsterdam (LASA), which also used accelerometers on the waist [34], indicating that physical activity data were, despite the small sample size, reliable.

In line with most previous studies, energy intake did not differ between patients with AD dementia and controls [8,9,10]. We additionally included a group of patients with MCI, who also showed a similar energy intake. Contrarily, one study observed a lower energy intake in patients with AD dementia than controls [7]. Discrepancies might be due to the use of two nonconsecutive 24-h recalls, which is a different method than we used and heavily relies on short term memory. We used two complementary methods to assess both habitual and actual dietary intake using an FFQ and food diary and observed a similar energy intake across methods. There were no associations of global cognition or AD biomarkers with energy intake, which further strengthens our finding that energy intake is not altered in mild to moderate AD. The mean energy intake of our population, around 2000 kcal, was higher compared to previous studies, ranging from 1500 to 1800 kcal, which is likely due to the higher age in these studies [7,8,9,10]. The energy intake of our population is comparable to the Dutch general older population [35, 36], indicating their dietary intake is reliable.

We investigated two components of energy balance (energy intake and energy expenditure), but other factors, like malabsorption, might also be important to explain malnutrition in AD patients and should be further investigated. For example, patients with AD dementia probably have a different microbiome than controls [37, 38]. Perhaps the altered microbiome affects nutrient uptake in the gut eventually leading to a negative energy balance. As unintended weight loss and malnutrition are associated with worse disease severity, understanding the malnutrition in dementia is important [39].

The strengths of this study include the use of two complementary dietary assessment methods and objective measurement of REE using indirect calorimetry in three, well diagnosed patient groups, including a group of patients with MCI. Dietary intake assessed by FFQ was available of a large sample compared to previous studies. We did not have CSF biomarkers of all participants and therefore performed a sensitivity analysis excluding participants without a matching biomarker profile. Results for dietary intake and REE did not change, indicating the results are reliable although diagnosis may not always be confirmed by CSF biomarkers. This study also has some limitations. First, because of the cross-sectional design, no causal inferences can be made. Future research should evaluate changes in body weight, energy intake, REE, and physical activity using a longitudinal design in order to investigate these aspects of energy balance across the different stages of the disease. Furthermore, we did not have any information about weight history, whether they lost or gained weight in the previous 6 months, which might hamper interpretation of an elevated REE. We currently follow our participants annually with neuropsychological assessments and body weight. Second, we do not have data of all our assessment methods for the total study sample. Participants with a valid measurement of REE (n = 88) were a selection of the FFQ sample (n = 219). Yet, participants with valid REE measurements did not differ in characteristics (sex, age, BMI and nutritional status) from the total sample. In addition, due to the small group with objective physical activity data available, analyses of REE could not be adjusted for physical activity, but were adjusted for fat-free mass instead. However, our data indicated no differences in physical activity between the diagnosis groups. For measurement of the REE, we used a standard-operating procedure, based on instructions by the manufacturer. The REE was continuously measured and the variability within the measurement was stable in all participants and did not differ across diagnosis groups. All participants were in rest during the measurement and no movements were observed. Lastly, in contrast to our expectations, diagnosis groups did not differ in BMI or MNA score. This is likely due to the small sample size. Given the higher REE and similar energy intake in patients with MCI and AD dementia, lower BMI and loss of body weight is expected. Unfortunately, we do not know the course of BMI or body weight of the participants before participating. Longitudinal studies are needed to investigate the REE and BMI change in relation to cognitive decline.

Conclusions

Patients with AD dementia and MCI had a higher REE than controls, while they did not consume more energy. These results provide support for the notion that higher REE, rather than reduced energy intake, underlies the frequently observed malnutrition in patients with AD dementia. This could suggest that patients with AD dementia and MCI should adjust their dietary intake to compensate their higher energy needs.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

AD:

Alzheimer’s disease

BMI:

Body mass index

CSF:

Cerebrospinal fluid

EN%:

Energy percentage

FFM:

Fat-free mass

FFQ:

Food frequency questionnaire

MCI:

Mild cognitive impairment

MMSE:

Mini-Mental State Examination

MNA:

Mini Nutritional Assessment

REE:

Resting energy expenditure

SCD:

Subjective cognitive decline

References

  1. Droogsma E, van Asselt D, van Steijn J, Veeger N, van Dusseldorp I, De Deyn PP. Nutritional interventions in community-dwelling Alzheimer patients with (risk of) undernutrition: a systematic review. Int Psychogeriatr. 2014;26:1–9.

  2. Lauque S, Arnaud-Battandier F, Gillette-Guyonnet S, Plaze JM, Andrieu S, Cantet C, et al. Improvement of weight and fat-free mass with oral nutritional supplementation in patients with Alzheimer’s disease at risk of malnutrition: a prospective randomized study. J Am Geriatric Society. 2004;52:1702–7.

    Article  Google Scholar 

  3. Vellas B, Guigoz Y, Garry P, Nourhashemi F, Bennahum D, Lauque S, et al. The mini nutritional assessment (MNA) and its use in grading the nutritional state of elderly patients. Appl Nutri Investigation. 1999;15(2):116–22.

    CAS  Google Scholar 

  4. Doorduijn AS, Visser M, Van de Rest O, Kester MI, De Leeuw FA, Boesveldt S, et al. Associations of AD biomarkers and cognitive performance with nutritional status: the NUDAD project. Nutrients. 2019;11(5):1161–70.

  5. Tamura BK, Bell CL, Masaki KH, Amella EJ. Factors associated with weight loss, low BMI, and malnutrition among nursing home patients: a systematic review of the literature. J Am Med Dir Assoc. 2013;14(9):649–55.

    Article  PubMed  Google Scholar 

  6. Singh S, Mulley G, Losowsky M. Why are Alzheimer patients thin? Age Ageing. 1988;17(1):21–8.

    Article  CAS  PubMed  Google Scholar 

  7. Shatenstein B, Kergoat MJ, Reid I. Poor nutrient intakes during 1-year follow-up with community-dwelling older adults with early-stage Alzheimer dementia compared to cognitively intact matched controls. J Am Diet Assoc. 2007;107(12):2091–9.

    Article  CAS  PubMed  Google Scholar 

  8. Dvorak RV, Poehlman ET. Appendicular skeletal muscle mass, physical activity, and cognitive status in patients with Alzheimer’s disease. Neurology. 1998;51:1386–90.

    Article  CAS  PubMed  Google Scholar 

  9. Tabet N, Mantle D, Walker Z, Orrell M. Higher fat and carbohydrate intake in dementia patients is associated with increased blood glutathione peroxidase activity. Int Psychogeriatr. 2005;17(1):91–8.

    Article  PubMed  Google Scholar 

  10. Puranen TM, Pietila SE, Pitkala KH, Kautiainen H, Raivio M, Eloniemi-Sulkava U, et al. Caregivers’ male gender is associated with poor nutrient intake in AD families (NuAD-trial). J Nutri Health Aging. 2014;18(7):672–6.

    Article  CAS  Google Scholar 

  11. Wolf-Klein GP, Silverstone FA, Lansey SC, Tesi D, Ciampaglia C, O’Donnell M, et al. Energy requirements in Alzheimer’s disease patients. Nutrition. 1995;11:264–8.

    CAS  PubMed  Google Scholar 

  12. Donaldson KE, Carpenter WH, Toth MJ, Goran MI, Newhouse P, Poehlman ET. No evidence for a higher resting metabolic rate in noninstitutionalized Alzheimer’s disease patients. J Am Geriatr Soc. 1996;44:1232–4.

    Article  CAS  PubMed  Google Scholar 

  13. Venturelli M, Ce E, Limonta E, Muti E, Scarsini R, Brasioli A, et al. Possible predictors of involuntary weight loss in patients with Alzheimer’s disease. PLoS One. 2016;11(6):e0157384.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Hartman YAW, Karssemeijer EGA, van Diepen LAM, Olde Rikkert MGM, Thijssen DHJ. Dementia patients are more sedentary and less physically active than age- and sex-matched cognitively healthy older adults. Dement Geriatr Cogn Disord. 2018;46(1–2):81–9.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Falck RS, Landry GJ, Best JR, Davis JC, Chiu BK, Luiu-Ambrose T. Cross-sectional relationships of physical activity and sedentary behavior with cognitive function in older adults with probable mild cognitive impairment. Phys Ther. 2017;97:975–84.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Folstein M, Folstein S, McHugh P. “Mini-mental state” a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975;12:189–98.

    Article  CAS  PubMed  Google Scholar 

  17. van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41(1):313–27.

    Article  PubMed  Google Scholar 

  18. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Beukers MH, Dekker LH, de Boer EJ, Perenboom CW, Meijboom S, Nicolaou M, et al. Development of the HELIUS food frequency questionnaires: ethnic-specific questionnaires to assess the diet of a multiethnic population in The Netherlands. Eur J Clin Nutr. 2015;69(5):579–84.

    Article  CAS  PubMed  Google Scholar 

  21. Meijboom S, van Houts-Streppel MT, Perenboom C, Siebelink E, van de Wiel AM, Geelen A, et al. Evaluation of dietary intake assessed by the Dutch self-administered web-based dietary 24-h recall tool (Compl-eat) against interviewer-administered telephone-based 24-h recalls. J Nutr Sci. 2017;6:e49.

    Article  PubMed  PubMed Central  Google Scholar 

  22. RIVM. Dutch food composition table (NEVO-tabel 2013). Bilthoven; 2013.

    Google Scholar 

  23. Willett WC. Issues in analysis and presentation of dietary data. New York: Oxford University Press; 1998.

    Book  Google Scholar 

  24. Weir J. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol Lond. 1949;109:1–9.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Troiano RP, Berrigan D, Dodd KW, Masse LC, Tilert T, McDowell M. Physical activity in the United States measured by accelerometer. Med Sci Sports Exerc. 2008;40(1):181–8.

    Article  PubMed  Google Scholar 

  26. Teunissen C, Petzhold A, Bennett J, Berven F, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73:1914–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem. 2010;56(2):248–53.

    Article  CAS  PubMed  Google Scholar 

  28. Tijms BM, Willemse EAJ, Zwan MD, Mulder SD, Visser PJ, van Berckel BNM, et al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-beta 1-42 analysis results. Clin Chem. 2018;64(3):576–85.

    Article  CAS  PubMed  Google Scholar 

  29. Verhage F. Intelligence and age in a Dutch sample. Hum Dev. 1965;8(4):238–45.

    Article  Google Scholar 

  30. Kyle UG, Genton L, Karsegard L, Slosman DO, Pichard C. Single prediction equation for bioelectrical impedance analysis in adults aged 20-94 years. Nutrition. 2001;17:248–53.

    Article  CAS  PubMed  Google Scholar 

  31. Ashraf A, Fan Z, Brooks DJ, Edison P. Cortical hypermetabolism in MCI subjects: a compensatory mechanism? Eur J Nucl Med Mol Imaging. 2015;42(3):447–58.

    Article  CAS  PubMed  Google Scholar 

  32. Ishii M, Wang G, Racchumi G, Dyke JP, Iadecola C. Transgenic mice overexpressing amyloid precursor protein exhibit early metabolic deficits and a pathologically low leptin state associated with hypothalamic dysfunction in arcuate neuropeptide Y neurons. J Neurosci. 2014;34(27):9096–106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Rosenberger ME, Haskell WL, Albinali F, Mota S, Nawyn J, Intille S. Estimating activity and sedentary behavior from an accelerometer on the hip or wrist. Med Sci Sports Exerc. 2013;45(5):964–75.

    Article  PubMed  PubMed Central  Google Scholar 

  34. van Ballegooijen AJ, van der Ploeg HP, Visser M. Daily sedentary time and physical activity as assessed by accelerometry and their correlates in older adults. Eur Rev Aging Phys Act. 2019;16:3.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Van Rossum CTM, Buurma-Rethans EJM, Vennemann FBC, Beukers MH, Brants HA, de Boer EJ, et al. The diet of the Dutch. 2016.

    Google Scholar 

  36. Elstgeest LEM, Winkens LHH, Penninx BWJH, Brouwer IA, Visser M. Associations of depressive symptoms and history with three a priori diet quality indices in middle-aged and older adults. J Affect Disord. 2019;249:394–403.

    Article  PubMed  Google Scholar 

  37. Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, et al. Gut microbiome alterations in Alzheimer’s disease. Sci Rep. 2017;7(1):13537.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Zhuang ZQ, Shen LL, Li WW, Fu X, Zeng F, Gui L, et al. Gut microbiota is altered in patients with Alzheimer’s disease. J Alzheimers Dis. 2018;63(4):1337–46.

    Article  CAS  PubMed  Google Scholar 

  39. White H, Pieper C, Schmader K. The association of weight change in Alzheimer’s disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc. 1998;46:1223–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. Wiesje van der Flier holds the Pasman chair.

We acknowledge members of the NUDAD project team:

Amsterdam University Medical Center location VUmc: Wiesje van der Flier, Maartje Kester, Philip Scheltens, Charlotte Teunissen, Marian de van der Schueren, Francien de Leeuw, Astrid Doorduijn, Heleen Hendriksen, Jay Fieldhouse, José Overbeek, Els Dekkers; Vrije Universiteit Amsterdam: Marjolein Visser; Wageningen University & Research: Ondine van de Rest, Sanne Boesveldt; DSM: Peter van-Dael, Manfred Eggersdorfer; Nutricia Research: John Sijben, Nick van Wijk, Amos Attali, J. Martin Verkuyl, Danielle Counotte; FrieslandCampina: Rolf Bos, Cecile Singh-Povel, Martijn Veltkamp, Ellen van den Heuvel.

Funding

Astrid Doorduijn, Francisca de Leeuw, and Heleen Hendriksen are appointed on a NWO-FCB grant (NUDAD; project number 057-14-004).

Author information

Authors and Affiliations

  1. Department of Nutrition and Dietetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health research institute, PO Box 7057, 1007 MB, Amsterdam, The Netherlands

    Astrid S. Doorduijn

  2. Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, PO Box 7057, 1007 MB, Amsterdam, The Netherlands

    Astrid S. Doorduijn, Francisca A. de Leeuw, Heleen M. A. Hendriksen, Philip Scheltens & Wiesje M. van der Flier

  3. Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands

    Marian A. E. de van der Schueren & Ondine van de Rest

  4. Department of Nutrition and Health, HAN University of Applied Sciences, Nijmegen, The Netherlands

    Marian A. E. de van der Schueren

  5. Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

    Francisca A. de Leeuw & Charlotte E. Teunissen

  6. Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam and the Amsterdam Public Health research institute, Amsterdam, The Netherlands

    Marjolein Visser

Authors
  1. Astrid S. Doorduijn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marian A. E. de van der Schueren
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ondine van de Rest
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francisca A. de Leeuw
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Heleen M. A. Hendriksen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Charlotte E. Teunissen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Philip Scheltens
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wiesje M. van der Flier
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Marjolein Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ASD drafted the manuscript and analyzed/interpreted data. MAEdvdS revised the manuscript and analyzed/interpreted data. OvdR revised the manuscript and interpreted data. FAdL revised the manuscript and interpreted data. HMAH revised the manuscript and interpreted data. CET revised the manuscript and interpreted data. PS revised the manuscript and interpreted data. WMvdF revised the manuscript and analyzed/interpreted data and supervised the project. MV drafted the manuscript, analyzed/interpreted data, and supervised the project. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Astrid S. Doorduijn.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the local Medical Ethical Committee. All participants provided written informed consent for their clinical data to be used for research purposes.

Consent for publication

Not applicable.

Competing interests

ASD, MAEdvdS, OvdR, FAdL, HMAH, and MV declare that they have no competing interests. CET is a member of the Innogenetics International Advisory Boards of Fujirebio/Innogenetics and Roche. PS has served as consultant for Wyeth-Elan, Genentech, Danone, and Novartis and received funding for travel from Pfizer, Elan, Janssen, and Danone Research. WMvdF performs contract research for Boehringer Ingelheim. Her research programs have been funded by ZonMW, NWO, EU-FP7, Alzheimer Nederland, CardioVascular Onderzoek Nederland, stichting Dioraphte, Gieskes-Strijbis fonds, Boehringer Ingelheim, Piramal Neuroimaging, Roche BV, Janssen Stellar. All funding is paid to her institution.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1; Supplementary Table A.

Characteristics of study samples of 3-day food diary, REE and physical activity.

Additional file 2: Supplementary Table B.

Dietary intake and energy expenditure according to diagnosis group, restricted to participants with a confirmed biomarker profile.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Doorduijn, A.S., de van der Schueren, M.A.E., van de Rest, O. et al. Energy intake and expenditure in patients with Alzheimer’s disease and mild cognitive impairment: the NUDAD project. Alz Res Therapy 12, 116 (2020). https://doi.org/10.1186/s13195-020-00687-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13195-020-00687-2

Keywords

Alzheimer's Research & Therapy

ISSN: 1758-9193